An Israeli breakthrough in brain disorder treatment has the ability to change lives!
The US Food and Drug Administration on Sunday permitted marketing of the Brainsway Deep Transcranial Magnetic Stimulation System for treatment of obsessive compulsive disorder (OCD).
Brainsway is an Israeli company dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders.
OCD is a common, chronic and long-lasting disorder in which a person has uncontrollable, recurrent thoughts and behaviors and feels the urge to repeat over and over. OCD is typically treated with medication, psychotherapy or a combination of the two. Although most patients with OCD respond to treatment, some patients continue to experience symptoms.
Transcranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate nerve cells in the brain. The FDA permitted marketing of TMS as a treatment for major depression in 2008 and expanded the use to include TMS for treating pain associated with certain migraine headaches in 2013.
Brainsway’s Deep TMS technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held across the globe.
“Transcranial magnetic stimulation has shown its potential to help patients suffering from depression and headaches,” said Dr. Carlos Peña, director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health. “With today’s marketing authorization, patients with OCD who have not responded to traditional treatments now have another option.”
With files from FDA.gov